Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Recommendation of “Hold” by Brokerages

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been assigned a consensus rating of “Hold” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $9.40.

Several brokerages recently weighed in on RXRX. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $10.00 to $11.00 in a research report on Wednesday, December 17th. UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Finally, Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $3.90 on Thursday. The firm’s fifty day moving average is $4.48 and its two-hundred day moving average is $4.96. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -2.17 and a beta of 0.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. Recursion Pharmaceuticals has a one year low of $3.71 and a one year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The business had revenue of $5.18 million during the quarter, compared to analyst estimates of $19.36 million. During the same quarter last year, the business posted ($0.34) EPS. The company’s revenue was down 80.1% on a year-over-year basis. Research analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Ben R. Taylor sold 21,383 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $4.18, for a total value of $89,380.94. Following the completion of the sale, the chief financial officer directly owned 761,550 shares in the company, valued at $3,183,279. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Najat Khan sold 124,403 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $4.41, for a total value of $548,617.23. Following the transaction, the insider directly owned 611,135 shares of the company’s stock, valued at approximately $2,695,105.35. The trade was a 16.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 585,786 shares of company stock worth $2,558,598. 8.43% of the stock is owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. TD Waterhouse Canada Inc. lifted its stake in Recursion Pharmaceuticals by 64.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after buying an additional 2,200 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $31,000. Sequoia Financial Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $41,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Recursion Pharmaceuticals by 97.2% during the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after acquiring an additional 4,446 shares during the last quarter. Finally, Allworth Financial LP lifted its position in shares of Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.